Drugs / GTI-2040

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT00459212 Mar 2007 → Dec 2010 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, inv(16)(p13.1;q22), acute myeloid leukemia, t(16;16)(p13.1;q22) +4 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00084643 May 2004 → Apr 2008 malignant colon neoplasm, rectal cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00078962 Jan 2004 → Nov 2007 cancer of unknown primary site National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00070551 Sep 2003 → Feb 2009 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT00074022 Oct 2003 → Nov 2007 non-small cell lung carcinoma, prostate carcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00056173 Mar 2002 → Dec 2004 metastatic neoplasm, renal cell carcinoma Aptose Biosciences Inc. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00565058 Aug 2007 → Sep 2009 acute myeloid leukemia Aptose Biosciences Inc. Completed No outcome recorded
Phase 2 NCT00087165 Jan 2005 → Sep 2006 prostate cancer University Health Network, Toronto Completed No outcome recorded
Phase 2 NCT00068588 Oct 2003 → Mar 2010 male breast carcinoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as GTI-2040 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00056173
8

NCT00459212

NCT00084643

NCT00087165

NCT00078962

NCT00565058

NCT00068588

NCT00074022

NCT00070551

Known as NSC 722929 “Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias” NCT00459212
Action Inhibit “GTI-2040 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.” NCT00070551
Modality Antisense oligonucleotide “an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA” NCT00056173
Route Intravenous “Given IV” NCT00068588